. GPR120 (also known as O3FAR1) functions as a receptor for unsaturated long-chain free fatty acids and has a critical role in various physiological homeostasis mechanisms such as adipogenesis, regulation of appetite and food preference 5, 6, [14] [15] [16] . Here we show that GPR120-deficient mice fed a high-fat diet develop obesity, glucose intolerance and fatty liver with decreased adipocyte differentiation and lipogenesis and enhanced hepatic lipogenesis. Insulin resistance in such mice is associated with reduced insulin signalling and enhanced inflammation in adipose tissue. In human, we show that GPR120 expression in adipose tissue is significantly higher in obese individuals than in lean controls. GPR120 exon sequencing in obese subjects reveals a deleterious non-synonymous mutation (p.R270H) that inhibits GPR120 signalling activity. Furthermore, the p.R270H variant increases the risk of obesity in European populations. Overall, this study demonstrates that the lipid sensor GPR120 has a key role in sensing dietary fat and, therefore, in the control of energy balance in both humans and rodents.
Free fatty acids provide an important energy source as nutrients, and act as signalling molecules in various cellular processes [1] [2] [3] [4] . Several G-protein-coupled receptors have been identified as freefatty-acid receptors important in physiology as well as in several diseases 3, [5] [6] [7] [8] [9] [10] [11] [12] [13] . GPR120 (also known as O3FAR1) functions as a receptor for unsaturated long-chain free fatty acids and has a critical role in various physiological homeostasis mechanisms such as adipogenesis, regulation of appetite and food preference 5, 6, [14] [15] [16] .
Here we show that GPR120-deficient mice fed a high-fat diet develop obesity, glucose intolerance and fatty liver with decreased adipocyte differentiation and lipogenesis and enhanced hepatic lipogenesis. Insulin resistance in such mice is associated with reduced insulin signalling and enhanced inflammation in adipose tissue. In human, we show that GPR120 expression in adipose tissue is significantly higher in obese individuals than in lean controls. GPR120 exon sequencing in obese subjects reveals a deleterious non-synonymous mutation (p.R270H) that inhibits GPR120 signalling activity. Furthermore, the p.R270H variant increases the risk of obesity in European populations. Overall, this study demonstrates that the lipid sensor GPR120 has a key role in sensing dietary fat and, therefore, in the control of energy balance in both humans and rodents.
To investigate the role of GPR120 in metabolism, we examined GPR120-deficient mice (Supplementary Fig. 1 ) with respect to lipogenesis, glucose and energy homeostasis. On a normal diet containing 13% fat, the body weight was similar in both GPR120-deficient and wildtype mice. However, when 5-week-old GPR120-deficient mice were fed a high-fat diet (HFD) containing 60% fat, their body weight increase was ,10% higher than that of wild-type mice on a HFD (Fig. 1a) . The difference in HFD-induced body weight gain between wild-type and GPR120-deficient mice was marked at ,8-10 weeks old and reached a plateau at 13 weeks old. To assess energy expenditure and substrate utilization, we next performed indirect calorimetry on wild-type and mutant mice on a HFD at 9-10 weeks old (Fig. 1b) and 15-16 weeks old ( Supplementary Fig. 2a ). The young GPR120-deficient mice showed decreased energy expenditure compared with the young wild-type mice, particularly during the light/inactive phase (Fig. 1b, left) , whereas older mutant and wild-type mice showed no such a difference ( Supplementary Fig. 2a , left). The difference in energy expenditure between GPR120-deficient and wild-type mice was observed only in the light phase, indicating that the lack of the GPR120 receptor primarily affects basal metabolism, especially in young mice. The decreased energy expenditure might explain the difference we found in body weight gain between HFD-fed wild-type and mutant young mice. The lower values of respiratory quotient in mutant mice could be due to insufficient glucose utility, probably as a result of the decreased insulin sensitivity. In all experiments, both groups of mice showed similar levels of locomotor activity (data not shown).
White adipose tissue (WAT) and liver were substantially heavier in HFD-fed GPR120-deficient mice ( Supplementary Fig. 2b ). Plasma low-and high-density lipoprotein cholesterol levels were significantly higher in HFD-fed GPR120-deficient mice, and serum alanine aminotransferase levels were substantially increased, indicating abnormal cholesterol metabolism and liver function (Supplementary Table 1) . Microcomputed tomography scanning revealed that 16-week-old GPR120-deficient mice stored much more fat than did wild type (Fig. 1c) . A significant increase in adipocyte size in both epididymal (Fig. 1d ) and subcutaneous ( Supplementary Fig. 2c ) fat was observed in GPR120-deficient mice. Furthermore, the expression of macrophage marker genes (Cd11b (Itgam), Cd68 and F4/80 (Emr1)) and the number of F4/80-positive cells were markedly enhanced in epididymal tissue from HFD-fed GPR120-deficient mice (Fig. 1e, f) . Moreover, these mice showed liver steatosis and hepatic triglyceride content was markedly increased (Fig. 1g) . Overall, HFD-induced obesity and liver fattiness were more severe in GPR120-deficient mice than in wild type.
Obesity-associated insulin resistance was also more severe in GPR120-deficient mice. HFD-fed GPR120-deficient mice showed higher levels of fasting plasma glucose and insulin than did wild type, although these parameters were similar between the two groups on a normal diet (Fig. 2a) . HFD-induced insulin resistance, as determined by an insulin tolerance test, was more prominent in GPR120-deficient mice than in wild type (Fig. 2b , left, and Supplementary Fig. 3a, b) . A glucose tolerance test further revealed that these mice suffered from impaired glucose metabolism (Fig. 2b , right, and Supplementary   Fig. 3a, b) . The level of plasma leptin was significantly higher in HFDfed GPR120-deficient mice than in wild type ( Supplementary Fig. 3c ). However, there was no significant difference in terms of plasma adiponectin level or food intake between the two groups (Supplementary Fig. 3d, e) . HFD-fed GPR120-deficient mice showed a marked increase in the size of islets and KI67 (MKI67)-positive cells, suggesting adaptive enlargement of the b-cell mass in response to insulin resistance 17, 18 ( Supplementary Fig. 3f, g ). Moreover, we observed markedly reduced peripheral insulin sensitivity in tissues from HFD-fed GPR120-deficient mice (Fig. 2c) . Insulin was shown to induce the phosphorylation of AKT (AKT1) (on Ser 473) in WAT, liver and skeletal muscle, with similar intensities in wild-type and GPR120-deficient mice on a normal diet ( Supplementary Fig. 3h ). Consistent with the insulin resistance reported above, HFD-fed GPR120-deficient mice showed loss of insulin-induced AKT phosphorylation in WAT and the liver.
To determine the molecular basis of the metabolic changes in WAT and livers of GPR120-deficient mice, we performed gene expression Red O-stained liver and hepatic triglyceride content after 24hr fasting (n 5 13). Scale bar, 50 mm. All data represent mean 6 s.e.m. *P , 0.05 and **P , 0.01 versus the corresponding wild-type value.
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analyses. We identified approximately 700 differentially expressed genes in WAT between HFD-fed GPR120-deficient and wild-type mice ( Supplementary Fig. 4a ). Connectivity mapping of these genes showed that pathways relating to insulin signalling and adipocyte differentiation were depressed, whereas those related to inflammation were enhanced in HFD-fed GPR120-deficient mice ( Supplementary  Fig. 4b ). Quantitative real-time PCR (qRT-PCR) analysis confirmed thedownregulationofinsulin-signalling-relatedgenes(Insr,Irs1andIrs2), an adipocyte differentiation marker gene (Fabp4) and a lipogenesisrelated gene (Scd1) in the epididymal fat from HFD-fed GPR120-deficient mice ( Fig. 2d and Supplementary Fig. 3i ). We identified approximately 100 differentially expressed genes in the liver between HFD-fed GPR120-deficient and wild-type mice ( Supplementary Fig. 5 ). Notably, lipogenesis-related genes (Scd1 and Me1) and a fatty acid transporter gene (Cd36) were significantly upregulated in livers from GPR120-deficient mice. Quantitative RT-PCR analysis confirmed upregulation of Scd1 in the liver of GPR120-deficient mice (Fig. 2d) . Western blot analysis further confirmed downregulation of IRb, IRS1 and SCD1 in adipose tissue of HFD-fed GPR120-deficient mice ( Fig. 2e ) but downregulation of IRS1 and IRS2 and upregulation of SCD1 in their livers (Fig. 2f) . Hence, insulin-signalling-related molecules were downregulated by the lack of GPR120 in both adipose tissue and the liver. However, the expression of SCD1, the rate-limiting enzyme in the biosynthesis of mono-unsaturated fatty acids, was downregulated in adipose tissue but upregulated in liver. Furthermore, the expression of Scd1 and several adipogenic genes 14, 19 (Pparg, Fabp4 and Srebf1) was suppressed in mouse-embryonic-fibroblast-derived adipocytes from GPR120-deficient mice, indicating that GPR120 is required for normal adipogenesis, as previously reported in differentiating 3T3-L1 adipocytes depleted of endogenous GPR120 by short interfering RNA 14 ( Fig. 2g, h ). To determine the effects of altered lipogenesis on lipid composition in GPR120-deficient mice, we performed lipidomics analysis in WAT, livers and plasma. Significant changes of major lipid clusters were observed ( Supplementary Fig. 6 ). Notably, the hepatic concentration of oleate (C18:1n9c) was significantly higher in HFD-fed GPR120-deficient mice than in wild type. The ratio of C18:1 to C18:0, an indicator of SCD1 enzyme activity [20] [21] [22] [23] , was markedly enhanced in livers from HFD-fed GPR120-deficient mice relative to wild type (Fig. 2i) . Moreover, the levels of C16:1n7 palmitoleate, which has recently been recognized as a lipid hormone 4 , in WAT and plasma were significantly lower in HFD-fed GPR120-deficient mice than in wild type (Fig. 2j ). In particular, lower levels of C16:1n7 palmitoleate were detected even in WAT of GPR120-deficient mice on a normal diet (Fig. 2j) , which seems to be in good agreement with the suppressed Scd1 expression and the reduced SCD1 desaturation index [20] [21] [22] [23] (C16:1/ C16:0; Fig. 2k, l) . Lipidomics analysis clearly illustrated dysregulated lipogenesis in GPR120-deficient mice, and showed the reduced production of lipid hormone C16:1n7 palmitoleate 4 . To determine whether the enhanced hepatic lipogenesis in GPR120-deficient mice was due to the reduced levels of C16:1n7 palmitoleate, we examined the effect of C16:1n7 palmitoleate treatment on hepatic Scd1 expression. A 6-h infusion of triglyceride:palmitoleate markedly lowered the enhanced hepatic Scd1 expression in GPR120-deficient mice (Fig. 2m) . The results indicated that the reduced C16:1n7 palmitoleate may explain the systemic metabolic disorders observed in GPR120-deficient mice on a HFD, as palmitoleate has been proposed to be a bioactive lipid by which adipose tissue communicates with distant organs (such as liver) and regulates systemic metabolic homeostasis 4 . This study shows that dysfunction of GPR120 can be an underlying mechanism for diet-associated obesity and obesity-related metabolic disorders in mouse.
The mouse data prompted us to assess the potential contribution of GPR120 to the development of obesity and its metabolic complications in humans. First, the expression levels of GPR120 in both subcutaneous and omental adipose tissues as well as in liver samples were compared between lean and obese subjects. Normoglycaemic obese patients and lean individuals (n 5 14 in each group) were matched for age and gender (Supplementary Table 2 ). As previously described 5, 14 , we confirmed that GRP120 is barely expressed in liver of either lean or obese subjects (data not shown). By contrast, we found that GPR120 is well expressed in the adipose tissue of lean individuals (Fig. 3a) . In addition, human obesity is significantly associated with an increase in GPR120 expression in both subcutaneous and omental adipose tissues (1.8-fold increase; P 5 0.0004 and P 5 0.003, respectively). We also found that GPR120 expression in subcutaneous adipose tissue strongly correlates with that in omental adipose tissue (Spearman analysis; r 5 0.570 and P 5 2.74 3 10 28 ), suggesting a systemic regulation of its expression in humans. Furthermore, we found a positive correlation between GPR120 expression in both subcutaneous and omental adipose tissues and in subjects' concentrations of plasma low-density lipoproteins (on adjustment for age and sex; r 5 0.247, P 5 0.0115 and r 5 0.255, P 5 0.0118, respectively).
To investigate the contribution of GPR120 to human obesity, the four GPR120 exons were sequenced in 312 French, non-consanguineous, extremely obese children and adults (Supplementary Table 3 ). We ] i response and GLP-1 secretion. a, GPR120 mRNA levels in human subcutaneous (SC) and omental (OM) adipose tissues of lean (LN; n 5 14) and obese (OB; n 5 14) normoglycaemic individuals. MannWhitney analysis, ***P 5 0.0004 and **P 5 0.003. Table 1 ). It is noteworthy that these results were almost the same after adjusting for geographical origin (Table 1) .
We then genotyped the p.R270H variant in 1,109 French pedigrees selected for obesity (n 5 5,045) and in 780 German trios with one obese child (n 5 2,340). We observed a significant over-transmission of the p.R270H low-frequency variant to obese offspring in 117 pedigrees or trios where the p.R270H variant was present (transmission, 62%; P 5 0.009; Supplementary Table 5 ). This family-based study excludes a hidden population stratification effect as a cause of spurious association.
We assessed the functional significance of both the p.R67C mutation and the p.R270H mutation in silico using several programs: arginine residues at positions 67 and 270 presented a high-evolutionaryconservation pattern among mammals and the two amino-acid substitutions were predicted to be potentially damaging (Supplementary Table 6 ). To examine the influences of the two non-synonymous variants on GPR120 function in vitro, we assessed each receptor ability to mobilize intracellular calcium (concentration, [Ca 21 ] i ) in response to the endogenous agonist a-linolenic acid (ALA). We found that ALA induced [Ca 21 ] i responses in T-REx 293 cells expressing either wildtype or p.R67C receptor in a dose-dependent manner, whereas ALA-induced [Ca 21 ] i responses in cells expressing p.R270H were significantly lower (P 5 1.6 3 10
25
) than those in cells expressing wild type at ALA concentrations greater than 10 mM (Fig. 3b) . We further examined the functional ability of the mutated receptors to secrete GLP-1 (ZGLP1) from human intestinal NCI-H716 cells, as this cell line lacks GPR120 expression and it can secrete GLP-1 in a regulated manner 5 . ALA induced secretion of GLP-1 in NCI-H716 cells expressing either wild-type (P 5 0.004) or p.R67C (P 5 3.2 3 10
) receptor, but not in NCI-H716 cells expressing p.R270H mutant (P 5 0.96) (Fig. 3c) . The transfection efficiencies for the GPR120 variant receptors were confirmed to be almost the same (data not shown). To examine the effect of the p.R270H variant on the wild-type receptor signalling, we analysed the [Ca 21 ] i dose-response curves after the transfection of an empty vector, a wild-type receptor plasmid or a p.R270H-mutated plasmid into T-REx 293 cells expressing wild-type GPR120. The transfection of the p.R270H-mutated plasmid suppressed dose-response curves, and the maximal ALA-induced [Ca 21 ] i response was significantly decreased (P 5 0.004; Fig. 3d) .
To assess the effect more quantitatively, we analysed [Ca
21
] i doseresponse curves in T-REx 293 cells stably expressing bicistronic wild-type/wild-type, wild-type/p.R270H or p.R270H/wild-type receptors (Fig. 3e, top) . Almost equal levels of receptor protein expression in each cell line were confirmed by flow cytometry analysis (Fig. 3e, ; Fig. 3e, bottom right) . These findings suggest that the p.R270H variant that is significantly associated with obesity has an inhibitory effect on GPR120. The p.R270H mutant lacks the ability to transduce the signal of long-chain free fatty acids, contrary to the p.R67C mutant, which did not associate with obesity.
To analyse whether being a p.R270H variant carrier may affect GPR120 expression in the adipose tissue, we quantified GPR120 expression in samples from both obese p.R270H carriers and obese noncarriers. Two hundred and thirty-eight obese normoglycaemic patients from the Atlas Biologique de l'Obésité Sévère cohort had already been genotyped for the p.R270H variant. Ten subjects heterozygous for the p.R270H variant were matched for age, gender and body mass index with ten non-carrier (wild-type) obese normoglycaemic patients (Supplementary Table 7 ). The expression of GPR120 was similar between p.R270H carriers and wild-type subjects, both in subcutaneous and omental adipose tissues ( Supplementary Fig. 7a ), suggesting that the presence of the functionally deleterious mutation has no primary or secondary effect on gene expression in fat depots. The adipogenesis marker PPARG, the lipogenesis-related factor SCD and the macrophage marker CD68 were found similarly well expressed in the adipose tissues of wild-type and p.R270H carrier patients ( Supplementary Fig. 7b, c) . Nevertheless, the expression of the fatty-acid-binding protein FABP4 in omental adipose tissue was significantly lower in p.R270H carriers than in wild-type individuals (28% decrease, P 5 0.043; Supplementary  Fig. 7b ).
Our results provide convincing evidence that the lipid sensor GPR120 is involved in obesity in both mice and humans. Given the role of GPR120 as a physiologic integrator of the environment (especially the fatty diet), these data provide insight into the molecular mechanisms by which the 'Westernized' diet may contribute to early-onset obesity and associated complications including non-alcoholic steatohepatitis. It also brings some understanding of the metabolic effects of the omega-3 fatty acids, which are often proposed as food supplements. This may open novel avenues of research for drug development in the treatment of obesity, lipid metabolism abnormalities and liver diseases, because receptors that sense free fatty acids represent attractive drug targets.
METHODS SUMMARY
GPR120-deficient mice were generated by deleting Gpr120 exon 1. All animal procedures and euthanasia were reviewed by the local animal care committee approved by local government authorities. Blood analysis, extraction and detection of mRNA and proteins, and immunohistochemical analysis, were performed following standard protocols as described previously 5, [24] [25] [26] . Details of antibodies, primers and probes are given in Methods. The level of significance for the difference between data sets was assessed using Student's t-test. Analysis of variance followed by Tukey's test was used for multiple comparisons. 
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In human, GPR120 expression in liver and in both omental and subcutaneous adipose tissues was assessed by quantitative RT-PCR (Taqman), in lean and obese subjects from the Atlas Biologique de l'Obésité Sévère cohort. The four GPR120 exons were sequenced in 312 French, extremely obese subjects following a standard Sanger protocol. The two identified non-synonymous variants (p.R270H and p.R67C/rs6186610) were subsequently genotyped in a large European obesity case-control study (n cases 5 6,942, n controls 5 7,654), by high-resolution melting analysis and TaqMan, respectively. The association between obesity status and each variant was assessed using logistic regression adjusted first for age and gender and then for age, gender and geography origin, under an additive model. The consequences of the two identified non-synonymous variants for GPR120 function ([Ca   21 ] i response and GLP-1 secretion) were assessed in vitro. The human study protocol was approved by the local ethics committee, and participants from all of the studies signed an informed consent form. 
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METHODS
Generation and genotyping of GPR120-deficient mice. GPR120-deficient mice on a mixed C57Bl/6/129 background were generated by homologous recombination. Exon 1 of the Gpr120 gene was replaced with a PGK-neo cassette (Supplementary Fig. 1 ). Animals. Mice were housed under a 12-hr light-dark cycle and given regular chow, MF (Oriental Yeast Co.). For HFD studies, 5-week-old male mice were placed on a 58Y1 diet (PMI Nutrition International) for a total period of 11 weeks. The methods used for animal care and experimental procedures were approved by the Animal Care Committee of Kyoto University. Indirect calorimetry. Twenty-four-hour energy expenditure and respiratory quotient (RQ) were measured by indirect calorimetry, using an open-circuit calorimeter system (MK-5000RQ, Muromachi Kikai Co.). Respiratory quotient is the ratio of carbon dioxide production to oxygen consumption (VO 2 ). Energy expenditure was calculated as the product of the calorific value of oxygen (3.815 1 1.232RQ) and VO 2 . Locomotor activity was measured by using an infrared-ray passive sensor system (Supermex, Muromachi Kikai Co.). Histology and immunohistochemistry. Epididymal adipose and pancreatic tissues were fixed in 10% neutral-buffered formalin, embedded in paraffin, and sectioned at 5 mm. H&E staining was performed using standard techniques. To measure the diameter of adipocytes and the area of pancreatic islets, the diameters of 100 cells from five sections from each group were measured using NIH IMAGE software. More than 10 fields were examined, islet area was traced and total islet area was calculated and expressed as the average score. Liver tissues were embedded in OCT compound (Sakura Finetech) and snap-frozen in liquid nitrogen. Tissue sections were stained with Oil Red O (Sigma-Aldrich) for lipid deposition using standard methods. Triglyceride content assay. To determine the triglyceride content of liver, tissue was homogenized with 1/2.5/1.25 (vol/vol) 0.5 M acetic acid/methanol/ chloroform. The mixture was shaken and 1.25 volumes of chloroform added. The mixture was shaken overnight and then 1.25 volumes of 0.5 M acetic acid added. After centrifugation at 1,500g for 10 min, the organic layer was collected, dried and resuspended in 100% isopropyl alcohol. Measurements were conducted using Triglyceride E-test Wako (Wako). Glucose tolerance and insulin tolerance tests. Glucose tolerance assays were performed on 24-hr-fasted mice. After baseline glucose values were individually established using One Touch Ultra (LifeScan), each mouse was given an intraperitoneal injection of 1.5 mg glucose per gram of body weight. Insulin tolerance was conducted using the same glucometer. After baseline glucose values were established, mice were given human insulin (0.75 mU g 21 intraperitoneal; Sigma-Aldrich). Clearance of plasma glucose was subsequently monitored at 15, 30, 60, 90 and 120 min post-injection. Immunoblot analysis. For insulin stimulation, 5 U insulin (Sigma-Aldrich) was injected through the inferior vena cava. Five minutes later, samples of liver, skeletal muscle or WAT were dissected and immediately frozen in liquid nitrogen. Immunoblot analysis were performed as described previously 5, 24, 25 . Anti-IRS1 (Millipore), anti-IRS2 (Millipore), anti-SCD1 (Santa Cruz Biotechnology), anti-IRb anti-AKT (Cell Signaling Technology), anti-p-AKT (Cell Signaling Technology) and anti-bactin (Sigma-Aldrich) antibodies were used as the primary antibodies. Mouse gene expression analysis. Total RNA was extracted from tissue or cells using ISOGEN (Nippon Gene). Quantitative RT-PCR and microarray analysis were performed as described previously 24, 26 . Briefly, genome-wide mRNA expression profiles were obtained by microarray analysis with the Affymetrix GeneChip Mouse 430 2.0 Array, according to the manufacturer's instructions. We used the robust multi-array analysis expression measure that represents the log-transformation of intensities (background corrected and normalized) from the GeneChips 27 . Functional associations between differentially expressed genes were analysed using Ingenuity Pathways Analysis (version 4.0, Ingenuity Systems). Microcomputed tomography scanning. Images were obtained using a microcomputed tomography system (SHIMADZU ClairvivoCT) with a high-resolution flat-panel detector. The maximum resolution of this modality was less than 40 mm. The scanner was assumed to have a cylindrical field of view of 65.3 mm in section view and of 300 mm in transaxial view. The X-ray source was biased at 60 keV with the anode current set to 160 mA. Computed tomography images were analysed with OSIRIX software (http://www.osirix-viewer.com/). Fatty acid composition of epididymal WAT, liver and plasma. Esterified and non-esterified fatty acid composition was measured by gas chromatography. Briefly, to analyse esterified fatty acid, samples of epididymal adipose tissue (20-25 mg) , liver (25-30 mg) and plasma (100 ml) were snap-frozen in liquid nitrogen and homogenized in 4 ml of 0.5 N KOH-methanol. Samples were then boiled at 100 uC for 30 min to hydrolyse. Total lipids in each sample homogenate were then extracted with hexane, followed by trans-esterification of fatty acids using boron trifluoride-methanol at 100 uC for 15 min. Methylated fatty acids were then extracted with hexane and analysed using a GC-2010AF gas chromatograph (SHIMADZU). For the analysis of non-esterified fatty acid, samples of epididymal adipose tissue (10-15 mg), liver (10-15 mg) and plasma (100 ml) were snapfrozen in liquid nitrogen and homogenized in a mixture of 1.2 ml water, 3 ml methanol and 1.5 ml chloroform. Total lipids in each sample homogenate were extracted with a mixture of 1.2 ml of water and 1.2 ml of chloroform, followed by silylation of fatty acids using N,O-bis(trimethylsilyl)trifluoroacetamide with 1% trimethylchlorosilane at 100 uC for 60 min. Silylated fatty acids were then extracted with hexane and analysed using a GC-2010AF gas chromatograph (SHIMADZU). Mouse embryonic fibroblast adipogenesis assay. To prepare MEFs, we minced 13.5-d-post-coital mouse embryos and digested them with trypsin. Cells were collected and cultured in modified Eagle's medium (a-MEM; supplemented with 10% fetal bovine serum (FBS), 50 U ml 21 penicillin and 50 mg ml 21 streptomycin). We induced confluent MEFs to undergo adipogenic differentiation by incubating them first for 2 d with 10 mg ml 21 insulin, 250 nM dexamethasone and 0.5 mM isobutylmethylxanthine (Sigma-Aldrich). We measured cellular triglyceride content with Triglyceride E-test Wako (Wako). Lipid infusion. Intralipid solution with 2 mM triglycerides:palmitoleate was prepared using a previously described protocol 4 . Briefly, lipids were dissolved in a solvent containing 5% glycerol and 0.72% phosphocholine in 0.9% saline and sonicated repeatedly. Lipids stayed in suspension for one week and had to be vortexed well before loading the syringe and tubing to prevent clogging. Before lipid infusion, mice were anaesthetized and an indwelling catheter was inserted in the left internal jugular vein. After overnight fasting, lipids were infused at a rate of 500 ml kg 21 h 21 for 6 h. At the end of the infusion, tissues were collected. Statistical analysis of the GPR120-deficient mouse study. The level of significance for the difference between data sets was assessed using Student's t-test. Analysis of variance followed by Tukey's test was used for multiple comparisons. Data were expressed as mean 6 s.e.m. P , 0.05 was considered to be statistically significant. Human study population. The study protocol was approved by all local ethics committees and informed consent was obtained from each subject before participation in the study, in accordance with the Declaration of Helsinki principles. For children younger than 18 years, an oral consent was obtained and parents provided written informed consent. All subjects were of European origin. Human gene expression analysis. We used liver, subcutaneous and omental adipose tissue samples from the Atlas Biologique de l'Obésité Sévère' (ABOS) cohort (ClinicalGov NCT01129297), a cohort studied in the Département de Chirurgie Générale et Endocrinienne 28 (Lille CHRU). Total RNA was extracted from the tissues using an RNeasy protect Mini Kit (QIAGEN) and quantified by absorbance at 260 nm and 280 nm in a PerkinElmer spectrophotometer. Human GPR120, FABP4, PPARG, CD68 and SCD mRNA levels were quantified by reverse transcription reaction followed by qRT-PCR. Quantitative assessment of human mRNA expression was performed using TaqMan Gene Expression Assays (Hs01111664_m1: GPR120 and Hs99999905_m1: GAPDH; Hs00609791_m1: FABP4; Hs00234592_m1: PPARG; Hs00154355_m1: CD68; Hs01682761_m1: SCD; Applied Biosystems) with an Applied Biosystems 7900HT Fast Real-Time PCR System. As an internal control for potential housekeeper reference variability, gene transcript levels were normalized to GAPDH reference housekeeper transcript level. The mean of the triplicate cycle thresholds of the target was normalized to the mean of triplicate cycle thresholds of the reference internal housekeeper genes using the formula 2 CTGAPDH {CTtarget , which yielded a relative target-to-reference transcript concentration value as a fraction of reference transcript. Samples for which the cycle threshold was above 35 were excluded from the analysis. GPR120 exon sequencing. We sequenced the four GPR120 exons in 312 obese patients including 121 French obese adults and 191 French obese children who were recruited by the CNRS-UMR8199 unit and the Department of Nutrition of Paris Hotel Dieu Hospital. GPR120 is located on human chromosome 10q23.33 and encodes a 377-amino-acid protein (NCBI NM_181745.3 and NP_859529). PCR conditions and primer sequences are available on request. Fragments were bidirectionally sequenced using the automated 3730xl DNA Analyzer (Applied Biosystems). Electrophoregram reads were assembled and analysed using the VARIANT REPORTER software (Applied Biosystems). The locations of the variants are displayed by base numbers counting from the ATG translation initiation codon following the Human Genome Variation Society nomenclature for the description of sequence variations. The positions of mutations were indicated by reference to the human genome build NCBI36/hg18. Genotyping of the p.R270H and p.R67C/rs6186610 variants. We genotyped the two non-synonymous variants in 6,942 unrelated obese subjects and in 7,654 control subjects, all of European descent. Genotyped populations are described in Supplementary 36 and from the Haguenau study 37 ; 148 Belgian lean subjects from Antwerp Hospital 33 ; and 469 Greek lean individuals recruited in medical examination centres in Thessaloniki 35 . The 1,109 French pedigrees selected for obesity were recruited by the CNRS-UMR8199 38 , and the 780 German childhood obesity trios were recruited at the Universities of Marburg and Essen 39 . The p.R270H variant was genotyped using the LightCycler 480 High Resolution Melting (HRM) Master kit (Roche), following the manufacturer's protocol. Genotyping of p.R67C/rs6186610 was performed using a custom TaqMan assay according to the manufacturer's instructions (Applied Biosystems). Allelic discrimination was performed using an Applied Biosystems 7900HT Fast RealTime PCR System and SDS 2.3 software. For both variants, genotype success rate was at least 95% and no deviation (P . 0.05) from Hardy-Weinberg equilibrium was observed in any of the examined populations. Phenotyping. The 90th and 97th body mass index (BMI) percentiles were used as thresholds for childhood overweight and obesity, respectively, according to the recommendations of the European Childhood Obesity Group study in local reference populations 40, 41 . Adult subjects were defined as normal (BMI , 25 kg m In silico analysis of both p.R270H and p.R67C variants. Phylogenetic conservation of the part of GPR120 containing each non-synonymous variant was assessed using the UCSC genome browser (Vertebrate Multiz Alignment & Conservation), based on a phylogenetic hidden Markov model, phastCons 42 . To predict the possible effect of both amino-acid substitutions on the structure and function of GPR120, we used several programs: the POLYPHEN (polymorphism phenotyping) web-based program 43, 44 ; PANTHER 45 (protein analysis through evolutionary relationships); the SIFT (sorting intolerant from tolerant) algorithm 46 ; the SNAP (screening for non-acceptable polymorphisms) software 47 
